Regeneron Pharmaceuticals Inc (REGN) Shares Sold by State of Tennessee Treasury Department

State of Tennessee Treasury Department decreased its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 54.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,776 shares of the biopharmaceutical company’s stock after selling 24,758 shares during the period. State of Tennessee Treasury Department’s holdings in Regeneron Pharmaceuticals were worth $8,051,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Capital World Investors boosted its stake in shares of Regeneron Pharmaceuticals by 6.6% in the third quarter. Capital World Investors now owns 7,810,538 shares of the biopharmaceutical company’s stock valued at $3,139,992,000 after buying an additional 483,912 shares in the last quarter. State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 3,240,549 shares of the biopharmaceutical company’s stock valued at $1,189,574,000 after buying an additional 68,675 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Regeneron Pharmaceuticals by 4.5% in the third quarter. Jennison Associates LLC now owns 2,122,148 shares of the biopharmaceutical company’s stock valued at $853,146,000 after buying an additional 91,223 shares in the last quarter. Artisan Partners Limited Partnership boosted its stake in shares of Regeneron Pharmaceuticals by 6.7% in the fourth quarter. Artisan Partners Limited Partnership now owns 1,891,598 shares of the biopharmaceutical company’s stock valued at $694,387,000 after buying an additional 118,896 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its stake in shares of Regeneron Pharmaceuticals by 49.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,715,305 shares of the biopharmaceutical company’s stock valued at $629,672,000 after buying an additional 567,188 shares in the last quarter. 68.83% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down 1.60% during midday trading on Friday, reaching $450.01. 996,846 shares of the company’s stock were exchanged. Regeneron Pharmaceuticals Inc has a 52 week low of $325.35 and a 52 week high of $462.96. The stock’s 50 day moving average is $397.84 and its 200 day moving average is $380.88. The firm has a market capitalization of $47.51 billion, a P/E ratio of 54.47 and a beta of 1.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The company had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.30 billion. During the same period in the previous year, the firm earned $2.57 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 9.8% on a year-over-year basis. On average, analysts expect that Regeneron Pharmaceuticals Inc will post $12.67 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was reported by Mideast Time and is the sole property of of Mideast Time. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.mideasttime.com/regeneron-pharmaceuticals-inc-regn-shares-sold-by-state-of-tennessee-treasury-department/1708074.html.

REGN has been the subject of several research reports. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 15th. Canaccord Genuity reaffirmed a “hold” rating and set a $375.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 30th. Goldman Sachs Group Inc cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Thursday, February 16th. Oppenheimer Holdings Inc. initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 16th. They issued a “hold” rating for the company. Finally, BMO Capital Markets reissued a “hold” rating and issued a $412.00 price target (up previously from $408.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 28th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $432.21.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the director now directly owns 3,000 shares in the company, valued at $1,350,000. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael S. Brown sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $400.00, for a total transaction of $400,000.00. Following the sale, the director now owns 1,000 shares of the company’s stock, valued at $400,000. The disclosure for this sale can be found here. 10.40% of the stock is owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

5 Day Chart for NASDAQ:REGN

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.